{"commentary":{"count":32,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":14,"podcast":10,"x_thread":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04404283\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ECHELON-3","nct_id":"NCT04404283","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=echelon-3-nct04404283. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ECHELON-3","arms":[{"description":"Brentuximab vedotin + lenalidomide + rituximab","label":"Experimental Arm","type":"EXPERIMENTAL"},{"description":"Placebo + lenalidomide + rituximab","label":"Control Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":{"count":239,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Brentuximab vedotin","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"last_update":"2026-07-22","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"Approximately 2 years"}],"references":[{"citation":"Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025 Mar 20;43(9):1061-1072. doi: 10.1200/JCO-24-02242. Epub 2025 Jan 7.","pmid":"39772655","type":"DERIVED"},{"citation":"Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2022 Mar 31;139(13):1999-2010. doi: 10.1182/blood.2021011894.","pmid":"34780623","type":"DERIVED"}],"start_date":{"date":"2020-08-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","url":"https://clinicaltrials.gov/study/NCT04404283"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/echelon-3-nct04404283"}